2020
A Single Institution Review Of Efficacy Of Neoadjuvant Chemoradiation With Gemcitabine/Abraxane Compared to FOLFIRINOX in Pancreatic Ductal Adenocarcinoma
Nguy S, Du K. A Single Institution Review Of Efficacy Of Neoadjuvant Chemoradiation With Gemcitabine/Abraxane Compared to FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e658-e659. DOI: 10.1016/j.ijrobp.2020.07.1972.Peer-Reviewed Original Research
2017
Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Oh P, Du K. Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. Current Colorectal Cancer Reports 2017, 13: 276-283. DOI: 10.1007/s11888-017-0376-3.Peer-Reviewed Original ResearchAdvanced rectal cancerRectal cancerNeoadjuvant chemoradiationComplete responsePathologic complete responseStandard of careBowel functionNeoadjuvant therapyOverall survivalTumor responsePotential complicationsChemoradiationBiologic factorsTreatment correlatesCancerSurgeryRecent reportsCurrent literatureBiomarkersResponseComplicationsPatientsTherapyCare
2014
Significantly Worse Colostomy-Free Survival in Human Immunodeficiency Virus–Positive Patients After Definitive Chemoradiation for Anal Cancer
Grew D, Bitterman D, Leichman C, Leichman L, Du K. Significantly Worse Colostomy-Free Survival in Human Immunodeficiency Virus–Positive Patients After Definitive Chemoradiation for Anal Cancer. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s398-s399. DOI: 10.1016/j.ijrobp.2014.05.1273.Peer-Reviewed Original ResearchChemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials
Min C, Bangalore S, Jhawar S, Guo Y, Nicholson J, Formenti SC, Leichman LP, Du KL. Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials. Oncology 2014, 86: 79-85. PMID: 24435019, DOI: 10.1159/000354641.Peer-Reviewed Original ResearchConceptsDisease-free survivalAdjuvant chemoradiationSurgical resectionOverall survivalRandomized trialsGastric cancerMantel-Haenszel random-effects modelHigher disease-free survivalCategory 1 recommendationNew systemic agentsR0 surgical resectionCurrent national guidelinesSignificant differencesRandom-effects modelAdjuvant chemotherapyPerioperative chemotherapyChemotherapy regimenChemoradiation therapySystemic agentsPrimary outcomeGastric adenocarcinomaClinical trialsChemoradiationNational guidelinesResection